Plantar Fasciitis Clinical Trials

Find Plantar Fasciitis Clinical Trials Near You

Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT in Heel Spur With Plantar Fasciitis

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The clinical picture of calcaneal spur with plantar fasciitis is a debilitating disease that is difficult to treat with conservative and interventional measures. Radiotherapy has shown very good therapeutic results in retrospective data, which need to be clinically confirmed both subjectively and in terms of image morphology in a prospective approach. Primary objective of the study: To demonstrate a clinical benefit of LDRT: improvement of pain, functionality and quality of life after LDRT

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:

• Age \> 39 years

• Typical clinical picture of plantar fasciitis for at least 3 months without associated trauma, other musculoskeletal co-morbidities or degenerative joint disease

• Patients with first-time application of LDRT to the affected joint

• Willingness to cooperate and accessibility of patients, especially geographical proximity, for treatment and follow-up

• Patients for whom LDRT is indicated independently of the study

• Karnofsky Index \>70%

Locations
Other Locations
Germany
Department of Radiation Oncology, Translational Radiobiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
RECRUITING
Erlangen
Contact Information
Primary
Thomas PD. Dr. med. Weissmann, MD
thomas.weissmann@uk-erlangen.de
+49913185
Backup
Lisa Dr. rer. nat. Weissmann, PhD
lisa.weissmann@uk-erlangen.de
+49913185
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 35
Treatments
Treatment Group
Radiotherapy with a guideline-compliant (Radiotherapy of benign diseases; specialist group-specific evidence-based S2e guideline of the German Society for Radio-Oncology (DEGRO)) single dose of 0.5 Gy (3.0 Gy total dose) over 3 weeks and, if pain persists, a second series with the same dosage at 12-week intervals.
Related Therapeutic Areas
Sponsors
Leads: University of Erlangen-Nürnberg Medical School

This content was sourced from clinicaltrials.gov